A mandate for all physicians far and wide is “Do No Harm.” A mandate in which the health of the patient is prioritized above all else, and the health benefits of any treatment should outweigh the risks of that treatment. This creates a situation in which life-saving therapies with powerful and sometimes dangerous side effects are easily justified, because without treatment a very serious diagnosis could kill the patient entirely.

​I’m pursuing a B.S. in Molecular, Cell, and Developmental Biology with a Minor in Society and Genetics at UCLA. My goal in college is to gain a deep understanding of human health, from the complex molecular mechanisms underlying disease to the broader social and political implications of the latest bioengineering technologies. Most of my background is in biological research and healthcare. Most recently, I conducted research on a pathogenic protein associated with Alzheimer’s and other neurodegenerative diseases at the UCSB Neuroscience Research Institute. I currently serve as a scribe for a primary care physician at UCLA Health.

Male Contraceptive Initiative’s mission is, “to empower men, and couples, to fully contribute to family planning goals by providing them the resources they need for reproductive autonomy.” It is how we articulate our most hopeful vision of the future: one where there is reproductive autonomy for all people. This vision and associated mission directs our daily activities, which encompass financial support to the male contraception research community and advocating for the development of additional male contraceptives.

The drug development process is often presented as a linear process: you achieve one milestone before moving on to the next, with progress taking the developer ever forward. The Food and Drug Administration defines this process as such:

• Discovery & Development: research for a new drug begins in the laboratory
  
• Preclinical Research: drugs undergo laboratory and animal testing to answer basic questions about safety
  
• Clinical Research: drugs are tested on people to make sure they are safe and effective 
  
• Food and Drug Administration Review: FDA review teams thoroughly examine all of the submitted data related to the drug or device and make a decision to approve or not to approve it
  
• FDA Post-Market Safety Monitoring: FDA monitors all drug and device safety once products are available for use by the public

Based on the way that this information is conveyed, you might expect the process to visually represent something like this:

Understanding people’s perspectives around male contraception helps guide our work at MCI. Sharing them is a privilege as well as a mandate: it’s of strategic importance to us to facilitate and broadcast the interest for male methods in an effort to present the undeniable market demand for them. Normally this is done through the lens of our grantees, fellows, research community, or even the general public. But lately, we’ve been endeavoring to share the views of MCI’s staff as well. In that spirit, this is a conversation with our Communications & Marketing Director Kevin Shane in which he shares his thoughts about male contraception as well as his interest in working with MCI. ​

​Oleksandr “Sasha” Kirsanov is a PhD candidate in the Geyer laboratory at East Carolina University’s Brody School of Medicine. His work is focused on defining the mechanisms underlying spermatogonial differentiation and meiotic initiation. In this blog post, Sasha shares about his work in the field of contraception, what he hopes to learn as an MCI fellow, and the future outlook of male contraception.

​Continuing our series sharing the thoughts and perspectives MCI staff has on male contraception, we sat down with our Program Coordinator Jaylan Weaver to hear his thoughts. Jaylan initially joined MCI as an undergraduate fellow, so he brings a unique perspective to a topic that means so much to all of us. In this post, he shares his motivations for working at Male Contraceptive Initiative as well as his thoughts about male contraception.

​We continue sharing thoughts and perspectives from MCI staff members with this conversation with our Advocacy Strategist Kathryn Carpenter. Kathryn initially joined MCI as a Fellow from the UNC Gillings School of Public Health and now champions many of our advocacy efforts including the creation and management of MCI’s Youth Advisory Board. In this post, she shares her motivations for working at Male Contraceptive Initiative as well as her thoughts about male contraception.